CTOs on the Move

MetaOptima Technology

www.metaoptima.com

 
MetaOptima: empowering users with advanced technologies MetaOptima is a digital health tech company dedicated to revolutionizing the dermatology and skin care industry with affordable, effective and intelligent tools. In order to provide state-of-the-art care, both medical professionals and their patients should be equipped with advanced tools. We are proud to offer two products designed to enhance the quality of patient care and organization while streamlining services for maximum efficiency: DermEngine and MoleScope. DermEngine is an intelligent skin analytics platform designed to provide medical experts with smart technologies to enhance workflows, organization and communications. MoleScope is a digital dermoscopic attachment for smartphones/tablets ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.metaoptima.com
  • 1055 W Georgia Street Suite 2275
    Vancouver, BC CAN V6E 3P3
  • Phone: 778 328 1949

Executives

Name Title Contact Details

Similar Companies

Nashville General Hospital at Meharry

Nashville General Hospital at Meharry is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Nashville General Hospital at Meharry is based in Nashville, TN. You can find more information on Nashville General Hospital at Meharry at www.nashvilleha.org

Society of Quality Assurance

Society of Quality Assurance is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthPort

HealthPort combines technology and strategic solutions to continually improve fragmented business processes for the healthcare community. The company offers revenue cycle management, electronic medical record, electronic document management, document

AlphaVax

AlphaVax is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Metamark

Metamark Genetics, Inc. is a privately held biotechnology company founded in 2007 to develop novel, function-based, prognostic and diagnostic tests aimed at improving cancer care. The company's proprietary genomic and proteomic discovery platforms have yielded significant discoveries in several disease areas, including prostate, colon, and breast cancers. In early 2014, Metamark plans to commercialize ProMark™—its prostate cancer prognostic test—through its Cambridge, Massachusetts CLIA-certified laboratory. For more information, please visit the company's Website at www.metamarkgenetics.com. Metamark™ and ProMark™ are trademarks of Metamark Genetics, Inc.